Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Mr. Charles E. Triano

Senior Vice President & Head of Investor Relations

Dr. Ginger  Gregory

Executive Vice President & Chief Human Resources Officer

Mr. Christopher A. Viehbacher

President, Chief Executive Officer & Director

Mr. Adam  Keeney Ph.D.

Executive Vice President & Head of Corporate Development

Mr. Michael R. McDonnell CPA

Executive Vice President & Chief Financial Officer

Ms. Robin C. Kramer

Senior Vice President & Chief Accounting Officer

Ms. Nicole  Murphy

Head of Pharmaceutical Operations & Technology

Ms. Natacha  Gassenbach

Chief Communication Officer & Head of Corporate Affairs

Ms. Alisha A. Alaimo

President & Head of North America

Ms. Susan H. Alexander Esq.

Executive Vice President & Chief Legal Officer

Име	Пазарна капитализация
Marksans Pharma Limited	0M
Luye Pharma Group Ltd.	0M
Virbac SA	0M
Daiichi Sankyo Company, Limited	0M
Astellas Pharma Inc.	0M
NGL Fine-Chem Limited	0M
Eli Lilly and Company	0M
Bristol-Myers Squibb Company	0M
Tonghua Dongbao Pharmaceutical Co., Ltd.	0M
Orion Oyj	0M
Chugai Pharmaceutical Co., Ltd.	0M

Biogen Inc.

Biogen Inc. Списък на конкурентите

Основни конкуренти